Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment
Jeffrey A. Cohen, Maria Trojano, Ellen M. Mowry, et al.
Multiple Sclerosis Journal (2019) Vol. 26, Iss. 1, pp. 23-37
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry
Cecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 74
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)
Ellen M. Mowry, Robert Bermel, James R. Williams, et al.
Frontiers in Neurology (2020) Vol. 11
Open Access | Times Cited: 70
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis
Tim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Neurology (2024) Vol. 102, Iss. 7
Open Access | Times Cited: 7
The need for a strategic therapeutic approach: multiple sclerosis in check
Hernán Inojosa, Undine Proschmann, Katja Akgün, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13
Open Access | Times Cited: 25
Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
Francesco Patti, Andrea Visconti, Antonio Capacchione, et al.
Therapeutic Advances in Neurological Disorders (2020) Vol. 13
Open Access | Times Cited: 38
E-health and multiple sclerosis
Paul M. Matthews, Valerie J. Block, Letizia Leocani
Current Opinion in Neurology (2020) Vol. 33, Iss. 3, pp. 271-276
Open Access | Times Cited: 32
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation
Frank Dahlke, Douglas L. Arnold, Piet Aarden, et al.
Multiple Sclerosis Journal (2021) Vol. 27, Iss. 13, pp. 2062-2076
Open Access | Times Cited: 32
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
Edward De Brouwer, Thijs Becker, Yves Moreau, et al.
Computer Methods and Programs in Biomedicine (2021) Vol. 208, pp. 106180-106180
Open Access | Times Cited: 31
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
Tim Spelman, Serkan Özakbaş, Raed Alroughani, et al.
Multiple Sclerosis Journal (2022) Vol. 29, Iss. 2, pp. 221-235
Open Access | Times Cited: 21
Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials
Jens Ingwersen, Lars Masanneck, Marc Pawlitzki, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Image harmonization improves consistency of intra-rater delineations of MS lesions in heterogeneous MRI
Aaron Carass, Danielle Greenman, Blake E. Dewey, et al.
Neuroimage Reports (2024) Vol. 4, Iss. 1, pp. 100195-100195
Open Access | Times Cited: 4
Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice
Moein Amin, Harvey M. Tucker, Dan Michael Pineda, et al.
Neurodegenerative Disease Management (2025), pp. 1-10
Open Access
Prognostic factors of disability progression in multiple sclerosis in real life: the OFSEP-high definition (OFSEP-HD) prospective cohort in France
Françis Guillemin, Cindy Romain, Jonathan Epstein, et al.
BMJ Open (2025) Vol. 15, Iss. 4, pp. e094688-e094688
Open Access
The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression
Cecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, et al.
Journal of Neurology (2020) Vol. 268, Iss. 4, pp. 1330-1341
Open Access | Times Cited: 30
Prevalence, Incidence, and Risk of Progression of Asymptomatic Pancreatic Cysts in Large Sample Real-world Data
Adam B. Schweber, Emil Agarunov, Christian Brooks, et al.
Pancreas (2021) Vol. 50, Iss. 9, pp. 1287-1292
Closed Access | Times Cited: 25
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years
Giulio Disanto, Marcello Moccia, Rosaria Sacco, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 58, pp. 103490-103490
Closed Access | Times Cited: 16
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
Tobias Moser, Tjalf Ziemssen, Johann Sellner
Wiener Medizinische Wochenschrift (2022) Vol. 172, Iss. 15-16, pp. 365-372
Open Access | Times Cited: 16
Improving the efficiency of clinical trials in multiple sclerosis
Ruth Ann Marrie, Maria Pia Sormani, Sean Apap Mangion, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 9, pp. 1136-1148
Open Access | Times Cited: 9
Data Collection in Multiple Sclerosis: The MSDS Approach
Tjalf Ziemssen, Raimar Kern, Isabel Voigt, et al.
Frontiers in Neurology (2020) Vol. 11
Open Access | Times Cited: 27
Recommendations for the use of propensity score methods in multiple sclerosis research
Gabrielle Simoneau, Fabio Pellegrini, Thomas P. A. Debray, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 9, pp. 1467-1480
Open Access | Times Cited: 15
Associations between multiple sclerosis and incidence of heart diseases: Systematic review and meta-analysis of observational studies
Daniel Rapp, Sebastian Michels, Jakob Schöpe, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 56, pp. 103279-103279
Open Access | Times Cited: 20
NARCOMS and Other Registries in Multiple Sclerosis
Ruth Ann Marrie, Gary Cutter, Robert J. Fox, et al.
International Journal of MS Care (2021) Vol. 23, Iss. 6, pp. 276-284
Open Access | Times Cited: 20
Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force
Tina Parciak, Lotte Geys, Anne Helme, et al.
Multiple Sclerosis Journal (2023) Vol. 30, Iss. 3, pp. 396-418
Open Access | Times Cited: 7
Harmonizing government responses to the COVID-19 pandemic
Cindy Cheng, Luca Messerschmidt, Isaac Bravo, et al.
Scientific Data (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Integrating large language models in care, research, and education in multiple sclerosis management
Hernán Inojosa, Isabel Voigt, Judith Wenk, et al.
Multiple Sclerosis Journal (2024)
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top